$CERS News

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

BTIG Upgrades Cerus to Buy, Announces $4 Price Target

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corp (NASDAQ:CERS) Surges on Strong Q1 Beat and Raised Guidance

Cerus Q1 2026 Earnings Call Transcript

Cerus Raises FY2026 Sales Guidance from $224.000M-$228.000M to $227.000M-$231.000M vs $242.400M Est

Cerus Q1 EPS $(0.01) Beats $(0.04) Estimate, Sales $53.661M Beat $53.167M Estimate

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

Cerus Signs Four-Year Supply Agreement With Établissement Français Du Sang For INTERCEPT Blood And Platelet Pathogen Inactivation System

Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Cerus Appoints COO Vivek Jayaraman To Company President And CEO Position Effective July 1

Cerus Appoints COO Vivek Jayaraman To Company President And CEO Position Effective July 1

Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference

Cerus's Record 2025 Sets It Up For Another Leg Higher

Cerus shares are trading lower after the company reported worse-than-expected Q4 sales results.

Cerus Corporation Q4 2025 Earnings Call Summary

Cerus Corp (CERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Cerus Q4 Earnings Call Highlights

Cerus Corp (NASDAQ:CERS) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss